PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsproctitis
MeSH D011349 - proctitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D005759:Gastroenteritis
$
Success rate
D012002:Rectal diseases
0 Companies
0 Drugs
Success rate
D011349: 
Proctitis
$
Success rate
D011350:Proctocolitis
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaMesalamine Mesalamine  2019-05-09   
PadagisMesalamine Mesalamine  2004-09-17   
MylanMesalamine Mesalamine  2018-11-20   
Mesalamine Sfrowasa 2027-07-24 1987-12-24   
SandozMesalamine Mesalamine  2019-06-12   
AllerganMesalamine Asacol  1992-01-31 $88.1 M Q2/19-Q1/20 
Mesalamine Mesalamine  2018-03-23   
TakedaMesalamine Lialda  2007-01-16   
Mesalamine Pentasa  1993-05-10   
Zydus TherapeuticsMesalamine Mesalamine  2017-06-05   
Sun Pharmaceutical IndustriesMesalamine Mesalamine  2019-01-25   
Alembic PharmaceuticalsMesalamine Mesalamine  2022-10-28   
Alkem LaboratoriesMesalamine Mesalamine  2021-07-15   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/0
Phase 2
100%
2/2
Phase 3
67%
2/3
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use